<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04449588</url>
  </required_header>
  <id_info>
    <org_study_id>STS-BDB001-04</org_study_id>
    <nct_id>NCT04449588</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS</brief_title>
  <official_title>A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Staidson (Beijing) Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Defengrui Biotechnology Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Staidson (Beijing) Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001
      injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory
      distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional
      treatment + BDB-001; Arm B: Conventional treatment alone).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Anticipated">August 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>28-day all-cause mortality rate</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving recovery in SpO2</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of PaO2/FiO2</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation time</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of oxygen therapy</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte count</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation indicators (CRP or IL-6) from baseline</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in body temperature</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&amp;D Blueprint during treatment period</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement at Day3, 7, 11 &amp; Day14 based on ordinal scale recommended by the WHO R&amp;D Blueprint during treatment period</measure>
    <time_frame>Baseline, Day 3, Day 7, Day 11, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to get categories 1 to 4 in the 8-points ordinal scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain an improvement of 1 point on the ordinal scale</measure>
    <time_frame>Baseline to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDB-001 Injection</intervention_name>
    <description>BDB-001 Injection+Conventional treatment</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years old ≤ age ≤ 80 years old, both men or women.

          2. Confirmed severe COVID-19 in less than 5 days who meets any of the following criteria:

               1. Respiratory distress, RR ≥ 30 times/min

               2. Finger oxygen saturation (SpO2) ≤93% in resting

               3. Oxygenation Index (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133kpa) in supine position

               4. Pulmonary imaging shows lesion progression &gt; 50% within 24-48 hours.

          3. Symptoms, signs or chest imaging indicates severe pneumonia or ALI/ARDS, requiring a
             mask oxygen therapy, nasal high-flow therapy (HFNC) or non-invasive positive pressure
             ventilation.

          4. The informed consent form signed.

        Exclusion Criteria:

          1. Subjects already progressed into critically severe COVID-19 (including respiratory
             failure requiring invasive mechanical ventilation, or shock, or combined with other
             organ failure which requires ICU administration) or sepsis and sepsis shock.

          2. History of severe lung disease such as chronic obstructive pulmonary disease (moderate
             to severe type), lung cancers, active tuberculosis; history of severe heart disease:
             unstable angina pectoris, myocardial infarction, postcardiac surgery, cardiac function
             ≥ grade 3 (NYHA Classification); history of severe liver diseases (e.g. Child-Pugh
             score ≥ grade C); history of severe kidney diseases, such as renal insufficiency (GFR
             ≤ 15 mL/min/1.73m^2); immune deficiencies or immune-related diseases : including organ
             or bone marrow transplantation, some autoimmune diseases, IgG4-related diseases,
             allergic alveolitis, vasculitis; malignancies.

          3. Subjects on current treatment with a complement inhibitor such as eculizumab.

          4. Subjects with hypersensitivity history to any ingredient contained in the drug.

          5. A subject has used the following drugs within 2 weeks prior to screening procedures:

               -  Immunesuppressive medicines (e.g., ciclosporin, tacrolimus, etc.)

               -  Proliferation inhibitors (e.g., everolimus, sirolimus, etc.)

               -  Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine
                  sulphate, etc.)

          6. Pregnant or lactating woman.

          7. Subjects who have participated in other clinical trials in the last 3 months or during
             this trial.

          8. Any other circumstances that the investigator considers inappropriate for the
             participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Mao, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Hospital of Chongqing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Du Zhouqi</last_name>
    <phone>+86 17600505723</phone>
    <email>duzhouqi@staidson.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southwest Hospital Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucan Jiang</last_name>
      <phone>+86 023 68754814</phone>
      <email>xnyyec@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUP Persahabatan(Persahabatan General Hospital)</name>
      <address>
        <city>East Jakarta</city>
        <state>Jakarta</state>
        <zip>13230</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erlina Burhan</last_name>
      <phone>08161628471</phone>
      <email>erlina_burhan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUD Pasar Minggu(Pasar Minggu General Hospital)</name>
      <address>
        <city>South Jakarta</city>
        <state>Jakarta</state>
        <zip>12550</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sri Dhuny Asri</last_name>
      <phone>0811181158</phone>
      <email>dhunyatasasri@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RSUD Cengkareng(Cengkareng General Hospital)</name>
      <address>
        <city>West Jakrata</city>
        <state>Jakrata</state>
        <zip>11730</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Puji Astuti</last_name>
      <phone>0818731171</phone>
      <email>pujiastutidr@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/15771587/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30229880/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/26060601/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/25433014/</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/23526211/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52. Review.</citation>
    <PMID>15771587</PMID>
  </reference>
  <reference>
    <citation>Wood AJT, Vassallo A, Summers C, Chilvers ER, Conway-Morris A. C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. Eur J Clin Invest. 2018 Dec;48(12):e13028. doi: 10.1111/eci.13028. Epub 2018 Oct 15. Review.</citation>
    <PMID>30229880</PMID>
  </reference>
  <reference>
    <citation>Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6. Review.</citation>
    <PMID>26060601</PMID>
  </reference>
  <reference>
    <citation>Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.</citation>
    <PMID>25433014</PMID>
  </reference>
  <reference>
    <citation>Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, Song H, Du L, Jiang S, Guo R, Tomlinson S, Zhou Y. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013 Aug;49(2):221-30. doi: 10.1165/rcmb.2012-0428OC.</citation>
    <PMID>23526211</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Severe Pneumonia</keyword>
  <keyword>ALI/ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

